XML 43 R30.htm IDEA: XBRL DOCUMENT
v3.10.0.1

License Agreements (Details) | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
May 31, 2018 USD ($) | Aug. 31, 2016 USD ($) Milestone | Dec. 31, 2012 USD ($) | Sep. 30, 2018 USD ($) | Jun. 30, 2018 USD ($) | Sep. 30, 2018 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Number of milestones | Milestone |  | 2 |  |  |  |
Merck |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Collaborative agreement, milestone payments paid | $ 3,000,000 |  |  |  |  |
Merck | License |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Licensing fee |  |  | $ 1,000,000 |  |  |
Merck | Development and Regulatory Milestones |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Collaborative arrangements, potential milestone payments |  |  | $ 25,000,000 |  |  |
JT Torii |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Accelerated recognition of deferred revenue, amount of revenue recognized |  |  |  |  | $ 8,100,000 |
Research and development arrangement, contract to perform for others, compensation earned |  |  |  |  | $ 2,000,000 |
JT Torii | Research and Development Arrangement |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Research and development arrangement, contract to perform for others, compensation earned |  |  |  | $ 0 |  | $ 10,600,000
JT Torii | Development and Regulatory Milestones |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Collaborative arrangements, potential milestone proceeds |  | $ 28,000,000 |  |  |  |
JT Torii | Collaboration Agreement |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Collaborative agreement, upfront payment received |  | 11,000,000 |  |  |  |
JT Torii | Commercial Milestone |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Collaborative arrangements, potential milestone proceeds |  | 15,000,000 |  |  |  |
JT Torii | Development and Regulatory Milestone, Preparation of Investigational New Drug Submission, Milestone One [Member] |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |
Collaborative arrangements, potential milestone proceeds |  | $ 2,000,000 |  |  |  |

X
- Definition Collaborative Agreement Milestone Payment Paid + References No definition available. + Details
Name: | mnlo_CollaborativeAgreementMilestonePaymentPaid
Namespace Prefix: | mnlo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Agreement, Upfront Payment Received + References No definition available. + Details
Name: | mnlo_CollaborativeAgreementUpfrontPaymentReceived
Namespace Prefix: | mnlo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangements, Potential Milestone Payments + References No definition available. + Details
Name: | mnlo_CollaborativeArrangementsPotentialMilestonePayments
Namespace Prefix: | mnlo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangements, Potential Milestone Proceeds + References No definition available. + Details
Name: | mnlo_CollaborativeArrangementsPotentialMilestoneProceeds
Namespace Prefix: | mnlo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of milestones. + References No definition available. + Details
Name: | mnlo_NumberOfMilestones
Namespace Prefix: | mnlo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References No definition available. + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=mnlo_MerckMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mnlo_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mnlo_JTToriiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_ResearchAndDevelopmentArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mnlo_CommercialMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mnlo_DevelopmentAndRegulatoryMilestonePreparationOfInvestigationalNewDrugSubmissionMilestoneOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |